All In Biotech

Investigational drug · Phase 2

RAPA-201 Rapamycin Resistant T Cells

Also called: RAPA-201 cells

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Malignant Melanoma, Malignant Melanoma With Metastasis, Malignant Melanoma Stage IIIc.

Phase 2

Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

3

Any phase or sponsor naming "RAPA-201 Rapamycin Resistant T Cells"

First trial start

2021

Aug 1, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "RAPA-201 Rapamycin Resistant T Cells", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Malignant Melanoma
  • Malignant Melanoma With Metastasis
  • Malignant Melanoma Stage IIIc
  • Malignant Melanoma Stage IV
  • Solid Tumor
  • Small Cell and Non-small Cell Lung Cancer
  • Head and Neck Cancer
  • Squamous Cell Carcinoma of Oral Cavity
  • Squamous Cell Carcinoma of Larynx
  • Squamous Cell Carcinoma of Nasopharynx

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Melanoma · Head and neck cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "RAPA-201 Rapamycin Resistant T Cells" as an intervention, largest first.

All trials
  • Rapa Therapeutics LLCIndustry

    NCT06708455 · 65 participants (planned) · Start Mar 1, 2027 · Primary completion Mar 1, 2029

    Drug: RAPA-201 Rapamycin Resistant T Cells; Chemotherapy Prior to RAPA-201 Therapy · For: Malignant Melanoma With Metastasis; Malignant Melanoma; Malignant Melanoma Stage IIIc and 1 more

    Sites: Hackensack, New Jersey

  • Rapa Therapeutics LLCIndustry

    NCT05144698 · 37 participants (planned) · Start Aug 1, 2021 · Primary completion Jan 1, 2026

    Drug: RAPA-201 Rapamycin Resistant T Cells; Chemotherapy Prior to RAPA-201 Therapy and 1 more · For: Solid Tumor; Small Cell and Non-small Cell Lung Cancer; Head and Neck Cancer and 6 more

    Sites: Hackensack, New Jersey

  • Rapa Therapeutics LLCIndustry

    NCT04176380 · 15 participants · Start Dec 2, 2020 · Primary completion Jan 30, 2023

    Drug: RAPA-201 Autologous T cells · For: Relapsed, Refractory Multiple Myeloma

    Sites: Milwaukee, Wisconsin

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Malignant Melanoma

  • Intismeran autogeneV940, mRNA-4157Phase 310 trials

    Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer

  • L19TNFL19IL2, OnfekafuspPhase 310 trials

    Philogen S.p.A. · Glioblastoma, Locally Advanced Basal Cell Carcinoma, Melanoma Stage III

  • DNA VaccinePhase 22 trials

    NEC Bio B.V · Triple Negative Breast Cancer, Malignant Melanoma, Melanoma (Skin)

  • TCC1727Phase 22 trials

    Beijing Tide Pharmaceutical Co., Ltd · Patients with Advanced Solid Tumors, Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer)

  • AMT-253Phase 21 trial

    Multitude Therapeutics Inc. · Malignant Melanoma, Advanced Solid Tumors

  • GM103Phase 21 trial

    GeneMedicine Co., Ltd. · Head and Neck Cancer, Malignant Melanoma, Colorectal Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.